Laura Surace

Laura Surace

Auto-generated profile, based on publicly available information

Laura Surace

Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, University of Bonn, Bonn, Germany

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in Cell
Verified
Journal Article
Closed access
ALAi Ing Lim
Ai Ing Lim
YLYan Li
Yan Li
SLSilvia Lopez-Lastra
Silvia Lopez-Lastra
RSRalph Stadhouders
Ralph Stadhouders
FPFranziska Paul
Franziska Paul
JSJames P. Di Santo
James P. Di Santo

14 December 2018 in Science Immunology
Verified
Journal Article
Closed access
PDF file
RMRubén Martínez-Barricarte
Rubén Martínez-Barricarte
JMJanet G. Markle
Janet G. Markle
CMCindy S. Ma
Cindy S. Ma
EDElissa K. Deenick
Elissa K. Deenick
NRNoé Ramírez-Alejo
Noé Ramírez-Alejo
JCJean-Laurent Casanova
Jean-Laurent Casanova
Hundreds of patients with autosomal recessive, complete IL-12p40 or IL-12Rβ1 deficiency have been diagnosed over the last 20 years. They typically suffer from invasive mycobacteriosis and, occasionally, from mucocutaneous candidiasis. Susceptibility to these infections is thought to be due to impairments of IL-12–dependent IFN-γ immunity and IL-23–dependent IL-17A/IL-17F immunity, respectively. We report here patients with autosomal recessive, complete IL-12Rβ2 or IL-23R deficiency, lacking responses to IL-12 or IL-23 only, all of whom, unexpectedly, display mycobacteriosis without candidiasis. We show that αβ T, γδ T, B, NK, ILC1, and ILC2 cells from healthy donors preferentially produce IFN-γ in response to IL-12, whereas NKT cells and MAIT cells preferentially produce IFN-γ in response to IL-23. We also show that the development of IFN-γ–producing CD4+ T cells, including, in particular, mycobacterium-specific TH1* cells (CD45RA−CCR6+), is dependent on both IL-12 and IL-23. Last, we show that IL12RB1, IL12RB2, and IL23R have similar frequencies of deleterious variants in the general population. The comparative rarity of symptomatic patients with IL-12Rβ2 or IL-23R deficiency, relative to IL-12Rβ1 deficiency, is, therefore, due to lower clinical penetrance. There are fewer symptomatic IL-23R– and IL-12Rβ2–deficient than IL-12Rβ1–deficient patients, not because these genetic disorders are rarer, but because the isolated absence of IL-12 or IL-23 is, in part, compensated by the other cytokine for the production of IFN-γ, thereby providing some protection against mycobacteria. These experiments of nature show that human IL-12 and IL-23 are both required for optimal IFN-γ–dependent immunity to mycobacteria, both individually and much more so cooperatively.

1 April 2015 in Immunity
Verified
Journal Article
Open access
LSLaura Surace
Laura Surace
VLVeronika Lysenko
Veronika Lysenko
AFAndrea Orlando Fontana
Andrea Orlando Fontana
VCVirginia Cecconi
Virginia Cecconi
HJHans Janssen
Hans Janssen
MBMaries van den Broek
Maries van den Broek
Radiotherapy induces DNA damage and cell death, but recent data suggest that concomitant immune stimulation is an integral part of the therapeutic action of ionizing radiation. It is poorly understood how radiotherapy supports tumor-specific immunity. Here we report that radiotherapy induced tumor cell death and transiently activated complement both in murine and human tumors. The local production of pro-inflammatory anaphylatoxins C3a and C5a was crucial to the tumor response to radiotherapy and concomitant stimulation of tumor-specific immunity. Dexamethasone, a drug frequently given during radiotherapy, limited complement activation and the anti-tumor effects of the immune system. Overall, our findings indicate that anaphylatoxins are key players in radiotherapy-induced tumor-specific immunity and the ensuing clinical responses.

24 February 2022 in Science
Verified
Journal Article
Closed access
NSNicolas SERAFINI
Nicolas SERAFINI
AJAngélique Jarade
Angélique Jarade
LSLaura Surace
Laura Surace
PGPedro Goncalves
Pedro Goncalves
OSOdile Sismeiro
Odile Sismeiro
JSJames P. Di Santo
James P. Di Santo
Group 3 innate lymphoid cells (ILC3s) are innate immune effectors that contribute to host defense. Whether ILC3 functions are stably modified after pathogen encounter is unknown. Here, we assess the impact of a time-restricted enterobacterial challenge to long-term ILC3 activation in mice. We found that intestinal ILC3s persist for months in an activated state after exposure to Citrobacter rodentium . Upon rechallenge, these “trained” ILC3s proliferate, display enhanced interleukin-22 (IL-22) responses, and have a superior capacity to control infection compared with naïve ILC3s. Metabolic changes occur in C. rodentium –exposed ILC3s, but only trained ILC3s have an enhanced proliferative capacity that contributes to increased IL-22 production. Accordingly, a limited encounter with a pathogen can promote durable phenotypic and functional changes in intestinal ILC3s that contribute to long-term mucosal defense.

28 July 2022 in Nature
Verified
Journal Article
Closed access
PDF file
FKFotios Karagiannis
Fotios Karagiannis
KPKonrad Peukert
Konrad Peukert
LSLaura Surace
Laura Surace
MMMarcel Michla
Marcel Michla
FNFabian Nikolka
Fabian Nikolka
CWChristoph Wilhelm
Christoph Wilhelm

22 October 2021 in Nature Immunology
Verified
Journal Article
Open access
PDF file
LSLaura Surace
Laura Surace
JDJean-Marc Doisne
Jean-Marc Doisne
CCCarys A. Croft
Carys A. Croft
ATAnna Thaller
Anna Thaller
PEPedro Escoll
Pedro Escoll
JSJames P. Di Santo
James P. Di Santo
Group 2 innate lymphoid cells (ILC2s) represent innate homologs of type 2 helper T cells (T H 2) that participate in immune defense and tissue homeostasis through production of type 2 cytokines. While T lymphocytes metabolically adapt to microenvironmental changes, knowledge of human ILC2 metabolism is limited, and its key regulators are unknown. Here, we show that circulating ‘naive’ ILC2s have an unexpected metabolic profile with a higher level of oxidative phosphorylation (OXPHOS) than natural killer (NK) cells. Accordingly, ILC2s are severely reduced in individuals with mitochondrial disease (MD) and impaired OXPHOS. Metabolomic and nutrient receptor analysis revealed ILC2 uptake of amino acids to sustain OXPHOS at steady state. Following activation with interleukin-33 (IL-33), ILC2s became highly proliferative, relying on glycolysis and mammalian target of rapamycin (mTOR) to produce IL-13 while continuing to fuel OXPHOS with amino acids to maintain cellular fitness and proliferation. Our results suggest that proliferation and function are metabolically uncoupled in human ILC2s, offering new strategies to target ILC2s in disease settings.